Plain-English translation of NCT07044544 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether two medications called and can be safely added to a stem cell transplant procedure for people with aggressive blood cancers like acute myeloid leukemia and myelodysplastic syndromes. The researchers want to see if adding these medications helps the transplant work better and keeps patients healthier. This is an early-stage study to figure out the right doses and watch for side effects.
Stem cell transplants can cure some blood cancers, but they don't work for everyone, especially people with high-risk disease. Researchers believe adding this medication before the transplant might improve survival and help the new stem cells work more effectively.
You likely qualify if…
You likely don't qualify if…
You will receive injections to boost your immune cells, followed by intravenous doses of the experimental medications over a few days before your transplant. Then you will undergo the standard stem cell transplant procedure. The study will closely monitor you for side effects and how well the treatment works, with checkups through at least day 28 after transplant and likely longer. The whole process typically requires hospital admission and takes several weeks.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
University of Alabama at Birmingham
Enrollment target
~20 participants
Started
July 2025
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Omer Jamy, MD
The University of Alabama at Birmingham
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.